Additionally, TRIM65 was identified as a significant oncogenic factor in urothelial carcinoma of the bladder (UCB) through screening of The Cancer Genome Atlas (TCGA) database and was validated in numerous clinical UCB tissue samples by Wei et al. Their study revealed that TRIM65 regulates cytoskeletal rearrangement and induces epithelial-mesenchymal transition in UCB cells through the ubiquitination of ANXA2, which ultimately enhances the invasiveness of these cells (Wei et al., 2018). The gene discussed is TRIM65; the disease is bladder transitional cell carcinoma.